#407 DIGEST: Bempedoic acid and cardiac risk, Alpha-Gal Syndrome, Orforglipron, Zuranolone, DOACs for VTE of Malignancy, mAbs for Dementia, New Med for Smoking Cessation, Kiwis and Constipation
The Curbsiders Internal Medicine Podcast
00:00
Trial on Non-Peptide GLP-1 Receptor Agonist for Weight Loss
This chapter discusses a trial on a non-peptide GLP-1 receptor agonist called Orforglipron for weight loss in adults with obesity or overweight and comorbidities related to weight. The study found significant weight loss and improvements in cardiometabolic profiles, with gastrointestinal side effects that can be minimized through optimized dosing.
Transcript
Play full episode
